Oral mucosal immunity and HIV infection: Current status

Oral Diseases

Volumn 8, Issue SUPPL. 2, 2002, Pages 55-62

  Challacombe, S J ^a   Sweet, S P ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Epithelium; HIV; IgA; Immunity; Mucosal; Saliva

Indexed keywords

CYSTATIN; CYTOKINE; IMMUNOGLOBULIN A; LACTOFERRIN; MUCIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; ANTIVIRUS AGENT; IMMUNOGLOBULIN; LEUKOCYTE ELASTASE INHIBITOR; MEMBRANE PROTEIN; PEPTIDE; PROLINE; PROTEIN; SALIVA PROTEIN; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY; PROLINE RICH PROTEIN; PROLINE-RICH POLYPEPTIDE;

ANTIBODY RESPONSE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUTH MUCOSA; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS; VACCINE PRODUCTION; BLOOD; DENDRITIC CELL; DISEASE PREDISPOSITION; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MACROPHAGE; PATHOGENICITY; PROLINE RICH PROTEIN DOMAIN; T LYMPHOCYTE; VIROLOGY;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYSTATINS; CYTOKINES; DENDRITIC CELLS; DISEASE SUSCEPTIBILITY; EPITHELIAL CELLS; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULINS; LACTOFERRIN; MACROPHAGES; MEMBRANE PROTEINS; MOUTH MUCOSA; MUCINS; PEPTIDES; PROLINE; PROLINE-RICH PROTEIN DOMAINS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; PROTEINS; SALIVARY PROTEINS AND PEPTIDES; T-LYMPHOCYTES; SALIVARY PROTEINS;

EID: 18744397582     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-0825.2002.00013.x     Document Type: Review

References (60)

1. Agace WW, Amara A, Roberts AI et al (2000). Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol 10: 325-328.
2. Baba TW, Liska V, Hofmann-Lehmann R et al (2000). Human neutralizing monoclonal antibodies of the IgG subtype protect asainst mucosal simian-human immunodeficiency virus infection. Nature Med 6: 200-206.
3. Baqui AA, Meiller TF, Falkler WAJ (1999). Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Clin Diag Laboratory Immunol 6: 808-811.
4. Becquart P, Hocini H, Levy M et al (2000). Secretory anti-human immunodeficiency virus (HIV) antibodies in colostrum and breast milk are not a major determinant of the protection of early postnatal transmission of HIV. J Infect Dis 181: 532-539.
5. Belec L, Dupre T, Prazuck T et al (1995). Cervicovaginal over-production of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J Infect Dis 172: 691-697.
6. Bergey EJ, Cho MI, Blumberg BM et al (1994). Interaction of HIV-1 and human salivary mucins. J AIDS 7: 995-1002.
7. Bomsel M, Heyman M, Hocini H et al (1998). Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9: 277-287.
8. Bukawa H, Sekigawa K, Hamajima K et al (1995). Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med 1: 681-685.
9. Challacombe SJ, Sweet SP (1997). Salivary and mucosal immune responses to HIV and its co-pathogens. Oral Dis 3 (Suppl. 1): S79-S84.
10. Coogan MM, Sweet SP, Challacombe SJ (1994). Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun 62: 892-896.
11. Cozon G, Biron F, Jeannin M et al (1994). Secretory IgA antibodies to Cryptosporidium parvum. AIDS patients with chronic cryptosporidiosis. J Infect Dis 169: 696-699.
12. Defer MC, Dugas B, Picard O et al (1995). Impairment of circulating lactoferrin in HIV-1 infection. Cell Molec Biol 41: 417-421.
13. Frick AG, Joseph TD, Pang L et al (2000). Haemophilia influence stimulates ICAM-1 expression on respiratory epithelial cells. J Immunol 164: 4185-4196.
14. Fultz PN (1986). Components of saliva inactivate human immunodeficiency virus. Lancet ii: 1215.
15. Geijtenbeek TB, Kwon DS, Torensma R et al (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
16. Grutter MG, Fendrich G, Huber R et al (1988). The 2.5 A X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. EMBO 7: 345-351.
17. Harmsen MC, Swart PJ, de Bethune MP et al (1995). Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 172: 380-388.
18. Hashemi FB, Spear GT, Madsen L et al (2000). Detection and molecular mass determination of an HIV replication-enhancing female genital tract factor using a blot bioassay. Biotechniques 28: 478-484.
19. Hladik F, Lentz G, Akridge RE et al (1999). Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract. J Virol 73: 5833-5842.
20. Hocini H, Bomsel M (1999). Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 179 (Suppl. 3): 448-453.
21. Huang GT, Haake SK, Kim JW et al (1998). Differential expression of interIeukin-8 and intercellular adhesion molecule-1 by human gingival epithelial cells in response to Actinobacillus actinomycetemcomitans or Porphyromonas gingivalls infection. Oral Micro Immunol 13: 301-309.
22. Johansson BG (1960). Isolation of an iron-containing red protein from human milk. Acta Chem Scand 14: 510-512.
23. Jung HC, Eckmann L, Yang S et al (1995). A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 95: 55-65.
24. Kato H, Bukawa H, Hagiwara E et al (2000). Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 18: 1151-1160.
25. Kaul R, Trabattoni D, Bwayo JJ et al (1999). HIV-1-spccific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13: 23-29.
26. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 164: 1602-1611.
27. Kuipers ME, de Vries HG, Eikelboom MC et al (1999). Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 45: 2635-2641.
28. Lamm ME (1997). Epithelial disposition of antigen. Aliment Pharmacol Therap 11 (Suppl. 3): 40-44.
29. Lehner T, Wang Y, Cranage M et al (1998). Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Dev Biol Standard 92: 225-235.
30. Lehner T, Bergmeier L, Wang Y et al (1999a). A rational basis for mucosal vaccination acainst HIV infection. Immunol Rev 170: 183-196.
31. Lehner T, Wang Y, Tao L et al (1999b). CD8-suppressor factor and beta-chemokine function as a complementary mechanism to cognate immunity. Immunol Let 66: 171-176.
32. Leigh J, Steele C, Wormley F et al (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J AIDS 19: 373-380.
33. Leung NJ, Aldovini A, Young R et al (2000). The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. Virology 268: 94-103.
34. Mascola JR, Stiegler G, VanCott TC et al (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med 6: 207-210.
35. McNeely TB, Dealy M, Dripps DJ et al (1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96: 456-464.
36. McNeely TB, Shugars DC, Rosendahl M et al (1997). Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90: 1141-1149.
37. Moja P, Tranchat C, Tchou I et al (2000). Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. J Infect Dis 181: 1607-1613.
38. Nagashunmugam T, Malamud D, Davis C et al (1998). Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus. J Infect Dis 178: 1635-1641.
39. Ogra PL, Mestecky J, Lamm ME et al (1999). Mucosal Immunology. Academic Press: San Diego.
40. Owen RL (1998). M cells as portals of entry for HIV. Pathobiol 66: 141-144.
41. Puddu P, Borghi P, Gessani S et al (1998). Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection. Int J Biochem Cell Biol 30: 1055-1062.
42. Quesnel A, Moja P, Lucht F et al (1994). Is there IgA of gut mucosal origin in the serum of HIV1 infected patients? Gut 35: 803-808.
43. Shugars DC (1999). Endogenous mucosal antiviral factors of the oral cavity. J Infect Dis 179 (Suppl. 3): S431-S435.
44. Skott P, Lucht E, Julander I et al (1999). Salivary sIgA response in HIV-1 infection. J AIDS 21: 73-80.
45. Smith PD, Li L, Meng G (1999). Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection. J Infect Dis 179 (Suppl. 3): S436-S440.
46. Staats HF, Ennis FA (1999). IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein. J Immunol 162: 6141-6147.
47. van der Strate BW, Harmsen MC, The TH et al (1999). Plasma lactoferrin levels are decreased in end-stage AIDS patients. Viral Immunol 12: 197-203.
48. Swart PJ, Kuipers EM, Smit C et al (1998). Lactoferrin. Antiviral activity of lactoferrin. Adv Exp Med Biol 443: 205-213.
49. Swart PJ, Harmsen MC, Kuipers ME et al (1999). Charge modification of plasma and milk proteins results in antiviral active compounds. J Peptide Sci 5: 563-576.
50. Sweet SP, Cookson S, Challacombe SJ (1995a). Candida albicans isolates from HIV-infected and AIDS patients exhibit enhanced adherence to epithelial cells. J Med Microbiol 43: 452-457.
51. Sweet SP, Rahman D, Challacombe SJ (1995b). IgA subclasses in HIV disease: dichotomy between raised levels in serum and decreased secretion rates in saliva. Immunology 86: 556-559.
52. Sweet SP, Denbury AN, Challacombe SJ (2001). Salivary calprotectin levels are raised in patients with oral candidiasis or Sjögren's syndrome but decreased by HIV infection. Oral Microbiol Immunol 16: 119-123.
53. Tomita M, Takase M, Bellamy W et al (1994). A review: the active peptide of lactoferrin. Ada Paediat Japonica 36: 585-591.
54. Ullrich R, Schmidt W, Zippel T et al (1998). Mucosal HIV infection. Pathobiology 66: 145-150.
55. VanCott TC, Kaminski RW, Mascola JR et al (1998). HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160: 2000-2012.
56. Vorland LH (1999). Lactoferrin: a multifunctional glycoprotein. APMIS 107: 971-981.
57. Wahl SM, McNeely TB, Janoff EN et al (1997a). Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis 3: S64-S69.
58. Wahl SM, Worley P, Jin W et al (1997b). Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. Am J Pathol 150: 1275-1284.
59. Zeitz M, Ullrich R, Schneider T et al (1998). Mucosal immunodeficiency in HIV/SIV infection. Pathobiology 66: 151-157.
60. Zinckgraf JW, Winchell JM, Silbart LK (1999). Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide. J Repro Immunol 45: 99-112.